JJ
NMRA icon

Johnson & Johnson’s Neumora Therapeutics NMRA Stock Holding History

Johnson & Johnson’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.61M Hold
1,849,445
– – 0.55% 11
2025
Q4 		$3.31M Hold
1,849,445
– – 0.6% 11
2025
Q3 		$3.37M Hold
1,849,445
– – 0.67% 12
2025
Q2 		$1.4M Hold
1,849,445
– – 0.42% 12
2025
Q1 		$1.85M Hold
1,849,445
– – 0.54% 13
2024
Q4 		$19.6M Hold
1,849,445
– – 5.08% 8
2024
Q3 		$24.4M Hold
1,849,445
– – 5.72% 9
2024
Q2 		$18.2M Hold
1,849,445
– – 4.54% 9
2024
Q1 		$25.4M Hold
1,849,445
– – 0.58% 9
2023
Q4 		$31.5M Buy
1,849,445
+937,317
+103% +$11.5M 0.72% 9
2023
Q3 		$12.9M Buy
+912,128
New +$11.4M 4.74% 6

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Johnson & Johnson's NMRA Position: Q1 2026 in Review

Johnson & Johnson held its Neumora Therapeutics (NMRA) position steady in Q1 2026 at 1,849,445 shares worth $3.61M. The position accounts for 0.55% of the portfolio, ranked #11.

Johnson & Johnson first reported a position in NMRA in Q3 2023 and has held it in 11 quarters since. The position peaked at $31.5M in Q4 2023. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Johnson & Johnson held 1,849,445 shares of Neumora Therapeutics worth $3.61M as of Q1 2026.
  • Johnson & Johnson left its Neumora Therapeutics share count unchanged in Q1 2026.
  • Neumora Therapeutics made up 0.55% of Johnson & Johnson's portfolio in Q1 2026, its #11 holding.
  • Johnson & Johnson first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Johnson & Johnson's Neumora Therapeutics position peaked at $31.5M in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Johnson & Johnson's 13F filing for Q1 2026, filed 13 May 2026.